tirzepatide news november 2025 In adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL Arti Thangudu MD|Endocrinologist (Diabetes/Thyroid/Weight Loss)

Store reconstituted vials refrigerated at 2 to 8 degrees Celsius

Tirzepatide produced a 21% average weight reduction in non-diabetics and was FDA approved for weight loss in 2023

They should also know that appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those who are overweight or obese, because of the obligatory weight gain that occurs in maternal tissues during pregnancy. At the same time, semaglutide can potentially help prepare a person for a successful pregnancy in the years and months before they plan to have a baby

(2025, August 19)

Its standout strengths are the interactive pricing tool, perfect shipping and packaging, no membership fee, and provider selection